Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

被引:113
作者
Smulevich, AB
Khanna, S
Eerdekens, M
Karcher, K
Kramer, M
Grossman, F
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium
[2] Natl Mental Hlth Res Ctr, Moscow, Russia
[3] Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Bangalore 560029, Karnataka, India
[4] Johnson & Johnson Pharmaceut Res & Dev, Titusville, NJ USA
关键词
bipolar disorder; haloperidol; mania; risperidone;
D O I
10.1016/j.euroneuro.2004.06.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In a randomized, double-blind trial, patients with acute bipolar mania received 1-6 mg/day of risperidone, 2-12 mg/day of haloperidol, or placebo for 3 weeks, followed by double-blind risperidone or haloperidol for 9 weeks. Of 438 patients, 154 were randomized to risperidone, 144 to haloperidol, and 140 to placebo. The mean+/-S.D. modal doses were 4.2+/-1.7 mg/day of risperidone and 8.0+/-3.6 mg/day of haloperidol during the initial 3-week phase and 4.1+/-1.8 and 7.4+/-3.7 mg/day during the 12-week period. At week 3, mean Young Mania Rating Scale (YMRS) score reductions from baseline were significantly greater in patients receiving risperidone than placebo (p<0.001). Differences between risperidone and haloperidol on this efficacy measure were not significant. Further reductions in YMRS scores were seen in patients receiving risperidone or haloperidol during the subsequent 9 weeks. No unexpected adverse events were reported. Extrapyramidal disorder and hyperkinesias, the most commonly reported adverse events with antipsychotic use, occurred less frequently with risperidone than haloperidol. We conclude that risperidone monotherapy was an effective and well-tolerated treatment for bipolar mania and that efficacy was maintained over the long term. (C) 2004 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码:75 / 84
页数:10
相关论文
共 55 条
[21]  
Kusumakar V, 1997, CAN J PSYCHIAT, V42, pS79
[22]   A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms [J].
Lemmens, P ;
Brecher, M ;
Van Baelen, B .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 99 (03) :160-170
[23]   Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials [J].
Leucht, S ;
Pitschel-Walz, G ;
Abraham, D ;
Kissling, W .
SCHIZOPHRENIA RESEARCH, 1999, 35 (01) :51-68
[24]  
LEYSEN JE, 1994, J CLIN PSYCHIAT, V55, P5
[25]   A review of psychosocial outcome in patients with bipolar disorder [J].
MacQueen, GM ;
Young, LT ;
Joffe, RT .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 103 (03) :163-170
[26]   Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania [J].
Miller, DS ;
Yatham, LN ;
Lam, RW .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (12) :975-980
[27]   Diagnostic and Statistical Manual of Mental Disorders [J].
Mittal, Vijay A. ;
Walker, Elaine F. .
PSYCHIATRY RESEARCH, 2011, 189 (01) :158-159
[28]   NEW DEPRESSION SCALE DESIGNED TO BE SENSITIVE TO CHANGE [J].
MONTGOMERY, SA ;
ASBERG, M .
BRITISH JOURNAL OF PSYCHIATRY, 1979, 134 (APR) :382-389
[29]  
MUKHERJEE S, 1986, ARCH GEN PSYCHIAT, V43, P342
[30]  
MURRAY CJL, 1996, GLOBAL BURDEN DIS IN, V1